JP2021530989A5 - - Google Patents

Info

Publication number
JP2021530989A5
JP2021530989A5 JP2021500868A JP2021500868A JP2021530989A5 JP 2021530989 A5 JP2021530989 A5 JP 2021530989A5 JP 2021500868 A JP2021500868 A JP 2021500868A JP 2021500868 A JP2021500868 A JP 2021500868A JP 2021530989 A5 JP2021530989 A5 JP 2021530989A5
Authority
JP
Japan
Prior art keywords
domain
igg1
domain monomer
monomer
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041306 external-priority patent/WO2020014419A2/en
Publication of JP2021530989A publication Critical patent/JP2021530989A/ja
Publication of JP2021530989A5 publication Critical patent/JP2021530989A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500868A 2018-07-11 2019-07-11 PD−L1を標的とした改変されたFc抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021530989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696711P 2018-07-11 2018-07-11
US62/696,711 2018-07-11
PCT/US2019/041306 WO2020014419A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1

Publications (2)

Publication Number Publication Date
JP2021530989A JP2021530989A (ja) 2021-11-18
JP2021530989A5 true JP2021530989A5 (cg-RX-API-DMAC7.html) 2022-07-20

Family

ID=69141681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500868A Withdrawn JP2021530989A (ja) 2018-07-11 2019-07-11 PD−L1を標的とした改変されたFc抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20210147549A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820998A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530989A (cg-RX-API-DMAC7.html)
KR (1) KR20210044782A (cg-RX-API-DMAC7.html)
CN (1) CN112996910A (cg-RX-API-DMAC7.html)
AU (1) AU2019299935A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106108A1 (cg-RX-API-DMAC7.html)
IL (1) IL280038A (cg-RX-API-DMAC7.html)
MX (1) MX2021000281A (cg-RX-API-DMAC7.html)
WO (1) WO2020014419A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024219897A1 (ko) * 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
TW202504932A (zh) * 2023-04-21 2025-02-01 南韓商百歲生命科學股份有限公司 包含兩個fc區域之抗原結合蛋白及其用途
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012819B1 (pt) * 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX360056B (es) * 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CA2972800A1 (en) * 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
RU2766890C2 (ru) * 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
JP2018529719A (ja) * 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
US12391759B2 (en) * 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
JP7080213B2 (ja) * 2016-03-23 2022-06-03 スーチョウ トランセンタ セラピューティクス カンパニー,リミテッド 新規抗pd-l1抗体
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
EP3507367A4 (en) * 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
EP3559032A1 (en) * 2016-12-23 2019-10-30 Innate Pharma Heterodimeric antigen binding proteins

Similar Documents

Publication Publication Date Title
JP2021532085A5 (cg-RX-API-DMAC7.html)
JP2021530498A5 (cg-RX-API-DMAC7.html)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
DE50210328D1 (de) Bispezifisches anti-cd28 antikörper-molekül
JP2020514301A5 (cg-RX-API-DMAC7.html)
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
ATE452147T1 (de) Antikörper mit korrigierten cdr
DE69327229D1 (de) Multivalente einkettige Antikörper
NZ597168A (en) Dual variable domain immunoglobin and uses thereof
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
WO2019089969A3 (en) Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
JP2021531756A5 (cg-RX-API-DMAC7.html)
EA202190542A1 (ru) Сконструированные биспецифические белки
DE602004021702D1 (de) Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen
PT1752471E (pt) Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
RU2007139953A (ru) Антитела к ccr5 и их применение
DK1697421T3 (da) Bispecifikke antistoffer
RU2013102596A (ru) МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРМАБЕЛЬНОЙ ОБЛАСТЬЮ α-ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ
CA3261607A1 (en) Antibody-drug combinations that bind to CDCP1 and their uses
JP2021531268A5 (cg-RX-API-DMAC7.html)
JP2010513228A5 (cg-RX-API-DMAC7.html)
IL307938B2 (en) Anti-c-met antibody drug conjugates
ATE490983T1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung